Lasmiditan
- Generic Name
- Lasmiditan
- Brand Names
- Reyvow, Rayvow
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18F3N3O2
- CAS Number
- 439239-90-4
- Unique Ingredient Identifier
- 760I9WM792
- Background
Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019. It was also approved by the European Commission on August 17, 2022.
...
- Indication
Lasmiditan is indicated for the acute treatment of migraine with or without aura in adults.
- Associated Conditions
- Migraine Headache, With or Without Aura
- Associated Therapies
- -
A Study of Lasmiditan on the Heart in Healthy Participants
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 56
- Registration Number
- NCT03465436
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Berlin, Germany
A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT03459612
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
🇺🇸Covance Clinical Research Inc, Madison, Wisconsin, United States
A Study of Lasmiditan in Healthy Elderly Participants
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT03406260
- Locations
- 🇺🇸
Covance Clinical Research Inc, Madison, Wisconsin, United States
A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT03310411
- Locations
- 🇺🇸
Covance Daytona Beach, Daytona Beach, Florida, United States
A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT03308669
- Locations
- 🇺🇸
Covance Madison CRU, Madison, Wisconsin, United States
A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users
- Conditions
- Interventions
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 96
- Registration Number
- NCT03286218
- Locations
- 🇺🇸
Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States
A Study of Lasmiditan and Propranolol in Healthy Participants
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 44
- Registration Number
- NCT03270644
- Locations
- 🇺🇸
Covance Daytona Beach, Daytona Beach, Florida, United States
A Study of Multiple Doses of Lasmiditan in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT03252015
- Locations
- 🇺🇸
Covance Daytona Beach, Daytona Beach, Florida, United States
A Study of Lasmiditan in Participants With Migraine
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT03247790
- Locations
- 🇺🇸
eStudySite, San Diego, California, United States
🇺🇸AGA Clinical Trials, Hialeah, Florida, United States
🇺🇸Meridien Research Inc., Tampa, Florida, United States
A Study of Lasmiditan in Healthy Participants
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT03182920
- Locations
- 🇺🇸
Covance Daytona Beach, Daytona Beach, Florida, United States
🇺🇸Covance Evansville, Evansville, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.